PASSAGE BIO INC (PASG)
US7027121000 - Common Stock
Overall PASG gets a fundamental rating of 2 out of 10. We evaluated PASG against 564 industry peers in the Biotechnology industry. PASG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PASG is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year PASG has reported negative net income.
In the past year PASG has reported a negative cash flow from operations.
PASG had negative earnings in each of the past 5 years.
In the past 5 years PASG always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of PASG (-61.56%) is worse than 60.32% of its industry peers.
Looking at the Return On Equity, with a value of -94.61%, PASG is in line with its industry, outperforming 47.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.56% | ||
| ROE | -94.61% | ||
| ROIC | N/A |
ROA(3y)-58.64%
ROA(5y)-47.13%
ROE(3y)-72.49%
ROE(5y)-56.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PASG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for PASG has been increased compared to 1 year ago.
The number of shares outstanding for PASG has been increased compared to 5 years ago.
There is no outstanding debt for PASG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PASG has an Altman-Z score of -8.60. This is a bad value and indicates that PASG is not financially healthy and even has some risk of bankruptcy.
PASG has a Altman-Z score of -8.60. This is in the lower half of the industry: PASG underperforms 71.63% of its industry peers.
There is no outstanding debt for PASG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.6 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 5.15 indicates that PASG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.15, PASG is in line with its industry, outperforming 54.94% of the companies in the same industry.
PASG has a Quick Ratio of 5.15. This indicates that PASG is financially healthy and has no problem in meeting its short term obligations.
PASG has a Quick ratio (5.15) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.15 | ||
| Quick Ratio | 5.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 42.93% over the past year.
EPS 1Y (TTM)42.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, PASG will show a very strong growth in Earnings Per Share. The EPS will grow by 21.19% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.68%
EPS Next 2Y28.03%
EPS Next 3Y16.8%
EPS Next 5Y21.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
PASG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PASG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PASG's earnings are expected to grow with 16.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.03%
EPS Next 3Y16.8%
5. Dividend
5.1 Amount
No dividends for PASG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PASSAGE BIO INC
NASDAQ:PASG (1/3/2025, 8:00:02 PM)
After market: 0.8149 -0.01 (-1.7%)0.829
0 (-0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners44.45%
Inst Owner Change2.22%
Ins Owners0.28%
Ins Owner Change0%
Market Cap51.21M
Analysts85.45
Price Target7.14 (761.28%)
Short Float %3.28%
Short Ratio2.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.18%
Min EPS beat(2)-32.14%
Max EPS beat(2)17.77%
EPS beat(4)3
Avg EPS beat(4)7.54%
Min EPS beat(4)-32.14%
Max EPS beat(4)26.8%
EPS beat(8)5
Avg EPS beat(8)2.26%
EPS beat(12)8
Avg EPS beat(12)6.53%
EPS beat(16)9
Avg EPS beat(16)2.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.5%
PT rev (3m)3.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)11.12%
EPS NY rev (3m)-7.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.7 | ||
| P/tB | 0.7 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.17
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS1.18
TBVpS1.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.56% | ||
| ROE | -94.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-58.64%
ROA(5y)-47.13%
ROE(3y)-72.49%
ROE(5y)-56.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.13% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.15 | ||
| Quick Ratio | 5.15 | ||
| Altman-Z | -8.6 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)604.02%
Cap/Depr(5y)663.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
EPS Next Y47.68%
EPS Next 2Y28.03%
EPS Next 3Y16.8%
EPS Next 5Y21.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.97%
EBIT Next 3Y10.1%
EBIT Next 5Y15.94%
FCF growth 1Y56.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.77%
OCF growth 3YN/A
OCF growth 5YN/A